Company Overview

Advanced Oxygen Technologies, Inc. (AOXY) is a U.S.-based company historically focused on the development and commercialization of medical technologies related to oxygen-based and oxidative therapies. Public disclosures indicate that the company has primarily operated at the intersection of healthcare technology and medical devices, with an emphasis on therapeutic oxygen delivery systems and related treatment concepts. The company has been quoted on U.S. public markets and has been subject to reporting obligations under U.S. securities regulations.

Based on available public filings and market disclosures, AOXY has experienced significant operational and strategic transitions over time, including periods of limited or suspended commercial activity. Its business model and revenue generation have been inconsistent, and the company has disclosed material uncertainty regarding its ability to continue as a going concern in certain reporting periods. Data inconclusive based on available public sources regarding sustained commercialization or stable revenue-producing operations.

Business Operations

Historically, Advanced Oxygen Technologies, Inc. reported a single operating segment centered on the research, development, and potential licensing or sale of oxygen-related medical technologies. The company has not consistently reported material revenues, and filings indicate that operations have often been limited to corporate maintenance, intellectual property positioning, and evaluation of strategic alternatives rather than active large-scale production or service delivery.

Publicly available information does not confirm the existence of significant domestic or international operating facilities, large-scale manufacturing assets, or long-term commercial partnerships. The company has disclosed reliance on third-party consultants and service providers for regulatory, scientific, and administrative functions. Data inconclusive based on available public sources regarding active subsidiaries, joint ventures, or recurring commercial contracts.

Strategic Position & Investments

AOXY’s disclosed strategic direction has historically emphasized identifying opportunities within emerging or alternative medical treatment technologies, particularly those involving oxidative or oxygen-enhanced therapeutic approaches. At various points, the company has indicated intentions to pursue acquisitions, licensing arrangements, or strategic investments to reposition or reactivate its business operations.

However, public filings and independent financial reporting indicate that many of these initiatives remained exploratory or contingent on financing. No major completed acquisitions or sustained investment programs have been consistently verified across multiple reporting periods. Data inconclusive based on available public sources regarding current strategic investments, operating subsidiaries, or exposure to emerging technologies with commercial validation.

Geographic Footprint

Advanced Oxygen Technologies, Inc. has primarily reported operations and corporate governance activities within the United States, with its headquarters historically registered in Nevada for corporate purposes. The company’s disclosures do not substantiate a meaningful operational presence across multiple U.S. states or international markets.

There is no verified evidence of sustained international operations, foreign subsidiaries, or overseas revenue streams. Any references to global market opportunities appear to be forward-looking or conceptual rather than reflective of an established geographic footprint. Data inconclusive based on available public sources regarding international operational influence.

Leadership & Governance

Public filings identify a small executive and governance structure, reflecting the company’s limited operational scale during recent reporting periods. Leadership roles have frequently changed, and governance has focused on regulatory compliance, capital structure management, and evaluation of strategic alternatives rather than operational expansion.

Verified executive leadership disclosed in regulatory filings includes:

• Michael B. Baker – Chief Executive Officer
• Michael B. Baker – President and Director

Information regarding additional executive officers, independent directors, or a broader senior management team cannot be consistently verified across multiple reputable public sources. Data inconclusive based on available public sources regarding a stable multi-executive leadership structure or articulated long-term management philosophy.